ENSC shares surge 32.91% intraday after first peer-reviewed clinical publication on MPAR(R) overdose protection.

Ensysce Biosciences surged 32.91% intraday trading following the announcement of its first peer-reviewed clinical publication demonstrating oral overdose protection with MPAR® technology. The study, published in a peer-reviewed journal, highlights the potential of the company’s proprietary technology to address opioid overdose risks, a significant unmet medical need. This development underscores progress in Ensysce’s pipeline and validates its scientific approach, likely attracting investor confidence. Other news items provided no specific details or were unrelated to the stock’s movement.